Business

MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant

BURLINGTON, Mass., June 18, 2025--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced Neoclease as the winner of the 2025 North American Advance Biotech Grant. The Boston-based biotech startup develops AI-designed gene editing therapies for Parkinson’s disease.

articleMerck KgaaJune 18, 20254/company/merck-kgaa/news/milliporesigma-announces-neoclease-as-winner-of-2025-north-american-advance-biotech-grant
MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant

About this update from Merck Kgaa

[{"type":"image","alt":"Neoclease receives Millipore Sigma’s North American Advance Biotech Grant.","displaySize":"","headline":null,"caption":"Neoclease receives Millipore Sigma’s North American Advance Biotech Grant.","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/c769453c6f750708278e8be7e8f4a3bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Swc0z7P1YkMEbqQliXy4zQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c769453c6f750708278e8be7e8f4a3bd","width":480,"height":480}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":274,"url":"https://media.zenfs.com/en/business-wire.com/9fd2b628af08dd2f34e50802da0e4605"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nXa8ji2QrBlmkqP1118v2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9fd2b628af08dd2f34e50802da0e4605","width":480,"height":274}}},{"type":"list","items":[{"val":[{"type":"text","content":"Winner’s lead therapy targets Parkinson’s disease; platform addresses 6,000+ genetic disorders","length":94,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Neoclease gains access to MilliporeSigma’s technologies and expert support to scale its AI-designed gene-editing platform","length":121,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The company has awarded 40+ startups globally through Advance Biotech Grant since 2014","length":86,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":301,"olType":false},{"type":"text","content":"BURLINGTON, Mass., June 18, 2025--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced Neoclease as the winner of the 2025 North American Advance Biotech Grant. The Boston-based biotech startup develops AI-designed gene editing therapies for Parkinson’s disease.","length":377,"tagName":"p"},{"type":"text","content":""We’re committed to empowering biotech innovators who are advancing transformative modalities like gene editing," said Sebastián Arana, Head of Pr...

More updates from Merck Kgaa

Merck KGaAMilliporeSigmaMillipore Sigma’s North American Advance Biotech GrantDarmstadt, GermanyAdvance Biotech GrantGrant ProgramParkinson’s diseaseBiotech Grantgene editinglife science business